FDA approves Sanofi’s Sarclisa combo for newly diagnosed multiple myeloma

The Food and Drug Administration announced it has approved isatuximab-irfc, or Sarclisa, from Sanofi-Aventis U.S. with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant, or ASCT. Full prescribing information for Sarclisa will be posted on Drugs@FDA, the agency stated.